Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)
Takuya Awata
Akira Shimada
Taro Maruyama
Yoichi Oikawa
Nobuyuki Yasukawa
Susumu Kurihara
Yumi Miyashita
Masako Hatano
Yuichi Ikegami
Masafumi Matsuda
Masataka Niwa
Youichiro Kazama
Shoichiro Tanaka
Tetsuro Kobayashi
10.6084/m9.figshare.5966986.v1
https://adisjournals.figshare.com/articles/figure/Possible_Long-Term_Efficacy_of_Sitagliptin_a_Dipeptidyl_Peptidase-4_Inhibitor_for_Slowly_Progressive_Type_1_Diabetes_SPIDDM_in_the_Stage_of_Non-Insulin-Dependency_An_Open-Label_Randomized_Controlled_Pilot_Trial_SPAN-S_/5966986
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0299-7"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced content for this article</strong><br>
If you are an author of this publication and would like to provide additional
enhanced content for your article then please contact <u>adisrapidplus@springer.com</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as ‘peer reviewed’ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides</p>
<p> </p>
2018-03-09 16:30:11
Dipeptidyl peptidase-4 (DPP-4) inhibitor
Intervention
Latent autoimmune diabetes in adults (LADA)
Prevention
Sitagliptin
Slowly progressive type 1 diabetes (SPIDDM)
Type 1 diabetes